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ABSTRACT: Acute renal failure (ARF) is rarely an iso-
lated process but is often a complication of underlying
conditions such as sepsis, trauma, and multiple-organ
failure in critically ill patients. As such, concomitant
clinical conditions significantly affect patient outcome.
Poor nutritional status is a major factor in increasing
patients’ morbidity and mortality. Malnutrition in ARF
patients is caused by hypercatabolism and hypermetabo-
lism that parallel the severity of illness. When dialytic
intervention is indicated, continuous renal replacement
therapy (CRRT) is a commonly used alternative to inter-
mittent hemodialysis because it is well tolerated by hemo-
dynamically unstable patients. This paper reviews the
metabolic and nutritional alterations associated with ARF
and provides recommendations regarding the nutritional,
fluid, electrolyte, micronutrient, and acid-base manage-
ment of these patients. The basic principles of CRRT are
addressed, along with their nutritional implications in
critically ill patients. A patient case is presented to illus-
trate the clinical application of topics covered within the
paper.
Acute renal failure (ARF) is a common complica-
tion experienced by critically ill patients. About
10%–30% of patients in the intensive care unit (ICU)
develop ARF, and 5%–10% of these patients are
treated with continuous renal replacement therapy
(CRRT).1–4 Morbidity and mortality rates in criti-
cally ill patients with ARF remain high and range
between 40% and 80%.1–4 This may reflect the fact
that patients in the ICU are now older, sicker, and
have more underlying comorbidities than in the
past.5 The goals of therapy for ARF are to limit
further renal injury; support the patient until kid-
ney function recovers; correct azotemia and the
fluid, electrolyte, and acid-base abnormalities; pre-
vent systemic complications; and permit nutrition
and other supportive therapies to be provided with
minimal limitation.1,6–8
ARF is characterized by the rapid decline in renal
function. As a result, excretion of nitrogenous waste
is compromised and fluid and electrolyte balance
cannot be maintained.9 Clinically, ARF is defined as
an acute elevation of the serum creatinine level from
baseline.9 Complete renal failure is evident when
the serum creatinine level rises by at least 0.5
mg/dL per day and urinary output falls below 400
mL per day.9 ARF can be stratified, in terms of
diagnosis and treatment, into 3 categories: prerenal,
intrinsic, and postrenal.9 Prerenal ARF is the result
of diminished blood flow to the kidneys.9 Intrinsic
ARF develops from damage to the renal paren-
chyma, and postrenal ARF is caused by an obstruc-
tion in the urinary tract.9
Malnutrition is common in patients with ARF
and is a likely contributor to increased morbidity
and mortality.2,5 Although providing nutrition sup-
port is important in critically ill catabolic patients,
the effects of nutrition support on reducing the
morbidity and mortality of ARF patients is yet to be
proven.7 The purpose of this paper is to review the
metabolic and nutritional alterations associated
with ARF, discuss nutrition support of ARF
patients, and address the nutritional implications of
various CRRT modalities.
Metabolic and Nutritional Aspects of ARF
Metabolic implications of ARF include hyperca-
tabolism, fluid and electrolyte abnormalities, and
metabolic acidosis. The metabolic response to stress
is associated with increased production of stress
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mediators, including the counterregulatory hormones
(catecholamines, cortisol, glucagon, growth hormone),
cytokines (interleukin-1, interleukin-6, tumor necro-
sis factor-), and other immune mediators (throm-
boxane A2, prostaglandin F2a, prostaglandin E2).
These stress mediators enhance proteolysis, glyco-
genolysis, gluconeogenesis, and lipolysis. The end
results are accelerated skeletal muscle catabolism,
impaired amino acid transport into skeletal mus-
cles, reduced insulin-mediated protein synthesis,
increased urea production, and peripheral insulin
resistance. These effects, in turn, lead to a negative
nitrogen balance, hyperglycemia, and hypertriglyc-
eridemia.1–2,6,10
The kidneys play a major role in regulating fluid,
electrolyte, and acid-base balance. In ARF, signifi-
cant imbalances in fluid, electrolytes, and acid-base
may occur. The magnitude of these imbalances var-
ies with the degree of renal impairment. The sever-
ity of renal injury and its effects on glomerular
filtration will dictate the extent of complications.
Adaptive mechanisms usually fail to correct these
disturbances because of the rapid nature of ARF. In
oliguric (urine output 100–400 mL/day) and anuric
(urine output 100 mL/day) renal failure, signifi-
cant fluid, electrolyte, and acid-base disturbances
occur compared with nonoliguric (urine output 400
mL/day) renal failure. Because ARF is rarely an
isolated entity but is often a complication of under-
lying conditions, coexisting diseases also contribute
to complications.
Fluids
Water Physiology
Water is approximately 60% of the adult body
mass. The intracellular fluid consists of fluids within
the cells and composes about two-thirds of total body
water. The extracellular fluid composes about one-
third of total body water and consists mainly of
plasma and interstitial fluid. Because of the gener-
ous perfusion of the kidneys, with the renal artery
carrying about 20% of the cardiac output, ARF
results in significant alteration in water filtration.
Fluid Imbalance
Oliguric and anuric ARF result in reduced renal
water excretion, leading to total body fluid overload.
Reduced urine output causes expansion of the extra-
cellular fluid volume and accumulation of a plasma
ultrafiltrate in the interstitial space or edema.
Insensible water losses continue to occur from the
gastrointestinal tract and skin and as a result of
metabolic activities. In oliguric ARF patients, fluid
intake is typically restricted to 500–1000 mL/day. In
nonoliguric ARF patients, urine volume is high,
negating the need for fluid restrictions. Patients
recovering from anuric renal failure or acute tubular
necrosis may have high urine water losses caused by
decreased tubular responsiveness to the effects of
antidiuretic hormone (ADH). Critically ill catabolic
patients have excess renal free water loss as a result
of the osmotic diuretic effects of increased urea
formation.11
Electrolytes
Sodium Homeostasis
Sodium is the major extracellular cation. It is the
most osmotically active substance that is responsi-
ble for water homeostasis and the regulation of the
extracellular fluid volume. Sodium exchanges occur
along the kidney tubule via different transport
mechanisms. Small variations in plasma sodium
levels cause changes in the release of ADH to regu-
late water balance.12
Sodium Imbalances
Changes in serum sodium levels commonly reflect
changes in water balance. In edematous patients
with fluid overload, hyponatremia may indicate a
dilutional effect. However, total body sodium may be
increased, decreased, or normal, depending on the
etiology of the hyponatremia.13 A sudden reduction
in the glomerular filtration rate in oliguric or anuric
ARF results in sodium retention. However, renal
sodium excretion is high, and sodium restriction is of
a lesser issue in the nonoliguric patient. Excessive
sodium intake in oliguric ARF patients increases
fluid retention and is common cause of diuretic
failure. As such, restriction of sodium intake in ARF
patients is necessary, especially in the case of fluid
retention. However, infusion of normal saline solu-
tions may be necessary when volume expansion and
increasing renal perfusion are indicated. Calcula-
tion of the fractional excretion of sodium helps
differentiate acute intrinsic renal failure from pre-
renal azotemia. A fractional excretion of sodium
1%–1.5% suggests acute renal tubular injury. A
fractional excretion of sodium 1% in oliguric
patients is characteristic of prerenal azotemia or
functional ARF. In either case, renal sodium conser-
vation is increased. However, there are cases of
acute intrinsic renal failure with a low fractional
excretion of sodium 1% such as ARF caused by
rhabdomyolysis, interstitial nephritis, and contrast-
dye nephrotoxicity. Caution should also be used in
the interpretation of the fractional excretion of
sodium in patients treated with diuretics where
urinary sodium excretion is increased.14 It is thus
crucial to interpret urinary sodium values in the
context of the patient’s medical history and clinical
presentation.
Potassium Homeostasis
Potassium is the most abundant intracellular
cation. About 90% of potassium is intracellular, 2%
is in the extracellular fluid, and the remaining
potassium is in the cartilage and bones. Most potas-
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sium is normally excreted via the kidneys. Potas-
sium is freely filtered at the glomerulus, and about
85% of potassium is reabsorbed in the proximal
tubule and loop of Henle. The cortical collecting duct
secretes and reabsorbs potassium. In case of excess
potassium intake that exceeds the kidney’s excre-
tion ability, the intracellular space temporarily
stores potassium until renal mechanisms can
excrete the potassium load. The H-K-ATPase
pump plays a major role in potassium handling in
the kidneys, and the Na-K-ATPase pump is the
rate-limiting step for potassium entry into the
cells.15
Potassium Imbalances
Because potassium is mainly excreted via the
kidneys, decreased glomerular filtration rate in ARF
patients results in hyperkalemia. Nonoliguric ARF
is unlikely to cause hyperkalemia, except in the case
of tubular defects or obstructive nephropathy. In
oliguric ARF, total urinary potassium excretion may
be 20 mEq/day. Other causes of hyperkalemia in
ARF patients may include cell turnover, intravascu-
lar hemolysis, acidosis, and the transfusion of hemo-
lyzed red blood cells. Cell turnover is typical of
catabolic ARF causing endogenous release of potas-
sium. Metabolic acidosis increases extracellular
potassium distribution that further increases serum
potassium levels.
Hyperkalemia can be extremely dangerous, caus-
ing life-threatening arrhythmias. Serum potassium
levels 6.5 mEq/L may result in severe cardiac
(bradycardia, arrhythmias with peaking T waves,
ventricular fibrillation) and neuromuscular (pares-
thesias, weakness) complications. These complica-
tions can be further aggravated if hypocalcemia
coexists. Severely hyperkalemic or symptomatic
patients should be treated with IV calcium glu-
conate or calcium chloride injections to antagonize
cardiac conduction abnormalities. Any exogenous
sources of potassium can rapidly increase serum
potassium levels in oliguric or anuric ARF
patients.15 Therefore, potassium intake should be
eliminated in anuric patients and restricted to
20–40 mEq/day in oliguric patients.
In nondialyzed patients with hyperkalemia, phar-
macologic interventions are needed to correct the
hyperkalemia by increasing intracellular potassium
distribution or increasing its elimination. Increased
intracellular potassium distribution is achieved
with the administration of sodium bicarbonate and
insulin. Concomitant dextrose infusion (D10W or
D50W) increases endogenous insulin secretion that
will further enhance intracellular potassium redis-
tribution and also avoids the possible hypoglycemia
induced by exogenous insulin administration. How-
ever, hyperglycemia should be avoided because it
increases extracellular potassium redistribution
and worsens hyperkalemia. Increased potassium
excretion can be achieved by the administration of
loop diuretics in diuretic-responsive patients. The
administration or sodium polystyrene sulfonate
orally or rectally binds intestinal potassium and
reduces potassium absorption. Serum potassium
levels should be followed closely, and potassium
supplements should only be administered as needed
to correct the hypokalemia when it occurs. IV potas-
sium is usually administered at infusion rates of
10–20 mEq/h.16,17
Phosphorus Homeostasis
About 85% of phosphorus is in the skeleton, 14%
in soft tissues, and only 1% in the extracellular
compartment. Phosphorus is the major intracellular
anion, mostly found in the forms of esters, adenosine
diphosphate, adenosine triphosphate, 2,3-diphos-
phoglycerate, and fructose 1,6-diphosphate. Physio-
logic regulators of phosphorus homeostasis involve
mainly the parathyroid hormone and vitamin D. The
kidneys are the major route of phosphorus excretion
by filtration mechanisms, with about 80%–90% of
phosphorus reabsorbed at the kidney tubule.12
Phosphorus Imbalances
Hyperphosphatemia is a common complication of
oliguric and anuric ARF. A less significant degree of
hyperphosphatemia occurs in nonoliguric ARF
patients. Hyperphosphatemia is the result of
decreased renal phosphorus excretion and increased
endogenous release of phosphates as a result of cell
lysis during hypercatabolism. Clinical manifesta-
tions of severe hyperphosphatemia are primarily the
result of calcium-phosphate precipitation. Meta-
static calcification in joints and soft tissues may
occur in renal-failure patients when the product of
serum calcium and phosphorus levels exceeds 60–70
mg/dL. Severe hyperphosphatemia may also cause
hypocalcemia and subsequent tetany. The treat-
ment of hyperphosphatemia consists of eliminating
all sources of phosphorus, administration of oral
phosphate binders, or treatment with dialysis if
necessary. IV calcium should not be used to treat
hyperphosphatemia as it may precipitate metastatic
calcification, hypotension, and renal failure. Phos-
phate binders such as calcium carbonate or calcium
acetate are most commonly used. Aluminum hydrox-
ide is another phosphate binder but carries the risk
of aluminum accumulation and toxicity in renal-
failure patients whose renal aluminum excretion is
impaired. In patients with concomitant hypercalce-
mia, sevelamer, a polymeric phosphate binder, can
be used to treat hyperphosphatemia without further
exacerbating the hypercalcemia.12
Magnesium Homeostasis
About 67% of magnesium is in the bones, 31% is
intracellular, and only 2% is in the extracellular
fluid. Most intracellular magnesium is bound to
proteins and phosphate compounds. About 60% of
178 Vol. 20, No. 2WOOLEY ET AL
magnesium in the plasma is in its free form, 25% is
protein-bound, and 15% is complexed to anions. The
kidneys, bones, and gastrointestinal tract regulate
magnesium homeostasis. Magnesium is primarily
excreted by the kidneys. Magnesium is freely fil-
tered in the glomerulus, with about 20%–30% reab-
sorbed in the proximal tubule, and up to 50% is
reabsorbed in the thick ascending loop of Henle.18
Only about 2% of magnesium is eliminated in
stools.19
Magnesium Imbalances
In oliguric and anuric ARF patients, reduced
renal magnesium elimination may result in hyper-
magnesemia. Clinical manifestations of hypermag-
nesemia depend on serum magnesium levels. Symp-
toms may affect the neuromuscular (lethargy,
nausea, confusion, muscle weakness), cardiovascu-
lar (hypotension, arrhythmias, cardiac arrest),
respiratory (respiratory depression), and neurologic
systems. Primary treatment of hypermagnesemia is
the removal of magnesium sources. In addition,
administering loop diuretics increases renal magne-
sium elimination. Symptomatic patients should be
treated with IV calcium chloride or calcium glu-
conate injection to antagonize and reverse the car-
diovascular and neuromuscular effects of magne-
sium.15
Calcium Homeostasis
Calcium has many functions, including its role in
bone metabolism, blood coagulation, platelet adhe-
sion, neuromuscular activity, endocrine and exo-
crine secretory functions, and electrophysiology of
heart and smooth muscles. Most of body calcium is
in the bones. Because approximately 45% of serum
calcium is bound to albumin, total serum calcium
levels should be adjusted for serum levels. For each
1 g/dL of serum albumin below 4 g/dL, total serum
calcium decreases by approximately 0.8 mg/dL. Cor-
rected serum calcium levels can be estimated as
follows:
Corrected serum calcium  measured serum cal-
cium  0.8  (4  measured albumin).
Because this equation may not accurately correct
for total serum calcium levels especially with very
low serum albumin levels, measurement of serum
ionized calcium is recommended. Serum ionized
calcium levels should be also interpreted in light of
the acid-base status. Metabolic alkalosis increases
calcium binding to serum proteins and lowers the
serum ionized calcium levels. Metabolic acidosis has
the reverse effect and decreases calcium binding to
serum proteins, resulting in increased serum ion-
ized calcium levels.20,21
Calcium Imbalances
In general, calcium disorders are not a major
problem in ARF as with chronic renal failure (CRF).
Hypocalcemia may occur more commonly than
hypercalcemia in ARF patients. The presence of
hypercalcemia in ARF patients should prompt rul-
ing out other causes such as malignancy, primary
hyperparathyroidism, adrenal insufficiency, vita-
min D toxicity, or milk-alkali syndrome. Hypercal-
cemia may also be caused by prolonged immobility.
Hypercalcemia as a cause of ARF should also be
ruled out.
Cases of hypocalcemia in ARF patients are
mainly because of hypoalbuminemia and do not
need treatment. Other causes of hypocalcemia may
include hypoparathyroidism, hypomagnesemia,
acute pancreatitis, malabsorption, hyperphos-
phatemia, loop diuretics, liver disease, vitamin D
deficiency, and citrated blood transfusions.12 Clini-
cal manifestations of hypocalcemia are variable and
depend on the acuity of the decrease in serum
ionized calcium levels. The hallmark sign of hypocal-
cemia is tetany. Symptoms may affect the neuro-
muscular (cramps, perioral paresthesias, weak-
ness), central nervous system (confusion, fatigue,
seizures, hallucinations) and cardiovascular (hypo-
tension, QT prolongation) systems. Acute or severe
hypocalcemia requires treatment with IV calcium
gluconate or calcium chloride. Calcium gluconate is
less irritating to the veins than calcium chloride and
is the IV calcium of choice for peripheral vein admin-
istration. Calcium chloride should be administered
via a central venous access because severe phlebitis
and tissue necrosis may occur if administered via a
peripheral vein.12
Acid-Base Disorders
The kidneys play a significant role in the regula-
tion of acid-base balance. This is because of the
buffering systems found along the kidney tubules
such as the Na-H pumps, ammonia and ammo-
nium systems, phosphates, bicarbonates, and
organic acids that regulate acid-base homeostasis.
In oliguric and anuric ARF, metabolic acidosis devel-
ops quickly. Metabolic acidosis results from the
inability of the kidneys to excrete hydrogen ions at
the distal tubule, inadequate bicarbonate synthesis
and reabsorption at the proximal tubule, decreased
ammonia production by the kidneys, and depletion
of available buffers. Failure of acid excretion results
in increased anion gap. The normal daily acid pro-
duction of about 1 mEq/kg causes reduction by 1
mEq/L of serum bicarbonate, resulting in bicarbon-
ate deficit. A catabolic state that is typical of ARF
may further worsen the metabolic acidosis, which in
turn hastens protein catabolism and muscle wasting.
Dialysis and administration of bicarbonate in these
patients would correct the metabolic acidosis. The
reversal of metabolic acidosis has been shown to halt
acidosis-related muscle wasting and improve nutri-
tional status.22–26
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Dialytic Intervention for ARF
A proactive and aggressive approach to the initi-
ation of dialytic intervention is recommended to
mitigate the metabolic derangements of ARF.7,27
There is controversy regarding the indications for
intermittent hemodialysis (IHD) vs CRRT in the
management of ARF.7 The advantages of CRRT
compared with IHD include superior uremic and
metabolic control; improved hemodynamic stability
and gas exchange; better fluid control; and facilita-
tion of sufficient nutrition support without the need
for protein, fluid, and electrolyte restrictions.3,7 Dis-
advantages of CRRT include the need for continuous
anticoagulation and patient immobility.7 Although
the immediate costs of CRRT may be as high as 2.5
times the cost of IHD, long-term costs of CRRT are
actually less expensive than IHD and can lead to
improved renal recovery.3
CRRT
Indications for CRRT
Although an individualized approach is ideal, an
established set of indications for the initiation of
CRRT exists. Indications for CRRT include nonob-
structive oliguria or anuria, severe metabolic acido-
sis, azotemia, severe hyperkalemia, suspected uremic
organ involvement (pericarditis, encephalopathy, neu-
ropathy, myopathy), severe dysnatremia, uncon-
trolled hyperthermia, diuretic-resistant edema or
anasarca, drug overdose with a dialyzable toxin, and
coagulopathy requiring large amounts of blood com-
ponents in patients with or at risk of pulmonary
edema or acute respiratory distress syndrome.6,9,28–30
Technology and Principles of CRRT
The technology of CRRT has undergone remark-
able growth over the last 25 years. In many ICUs,
especially in Australia and Europe, CRRT is the
primary, if not exclusive, form of dialytic interven-
tion used for ARF.27 Once proper vascular access
has been established using a dual-lumen central
venous catheter specifically designed for dialysis,
blood flows through a semipermeable membrane
called a hemodiafilter. Blood flow is pressure driven
either by using a peristaltic pump during veno-
venous hemodiafiltration or by relying on the
patient’s own blood pressure during arteriovenous
hemodiafiltration. The hemodiafilter consists of a
high- or low-flux synthetic membrane. When blood
passes through the hemodiafilter, removal of fluid
and solutes can be achieved by diffusion, convection,
or a combination of both, depending on the CRRT
modality used.1,29
CRRT encompasses dialytic modalities that differ
according to the mechanisms used to achieve fluid
and solute clearance. Significant practice variations
exist with respect to CRRT.3 In the interest of
standardization and clarity, it is recommended to
use the proposed nomenclature and common terms
related to CRRT as defined by a consensus panel of
experts (Table 1).31
The 4 most commonly used CRRT modalities are
continuous venovenous hemodialysis (CVVHD), con-
tinuous venovenous hemofiltration (CVVH), contin-
uous venovenous hemodiafiltration (CVVHDF), and
slow continuous ultrafiltration (SCUF) (Table 2).
Continuous arteriovenous therapies were originally
used because they did not need a peristaltic pump,
but the morbidity associated with arterial cannula-
tion has led to their wide abandonment.
During CVVHD, solutes are removed primarily
by diffusion across a semipermeable membrane.
Diffusion is concentration gradient dependent.
CVVHD uses the same principle as IHD with a
dialysate that runs countercurrent to the blood on
the other side of the hemodiafilter. CVVHD is used
in situations where the main goal is to control blood
concentrations of small solutes like urea, creatinine,
Table 1
Important nomenclature and common terms related to continuous renal replacement therapy31
Term Definition
Diffusion Solute and plasma water removal generated by a concentration gradient
Convection Solute and plasma water removal generated by a pressure gradient
Ultrafiltration A process whereby plasma water and solutes are separated from the blood across a
semipermeable membrane that is driven by transmembrane pressure
Ultrafiltrate The plasma water and solutes produced by ultrafiltration of the blood during continuous
venovenous hemofiltration
Effluent The plasma water and solutes produced by dialysate during continuous venovenous
hemodialysis or continuous venovenous hemodiafiltration
Dialysate A solution that passes through the hemodiafilter to achieve plasma water and solute clearance
by diffusion
Venovenous circuit Venous vascular access and associated tubing designed to carry blood into the hemodiafilter
and back into circulation
Predilution (prefilter) The administration of fluid into the patient’s blood before it enters the hemodiafilter
Postdilution (postfilter) The administration of fluid into the patient’s blood after it leaves the hemodiafilter
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or electrolytes. Diffusion depends on the concentra-
tion gradient, molecular weight (speed, size), mem-
brane resistance (material: high-flux membranes,
thickness, number and size of pores), and protein-
bound membrane toxins (solute-free fraction).29
With CVVH, dissolved solutes not restricted by
the pore size of the membrane are transported along
with the solvent via a solvent drag mechanism
called convection. This filtration is directly propor-
tional to the ultrafiltration rate at which plasma
water traverses the semipermeable membrane and
to the permeability of the membrane. Ultrafiltrate is
the plasma water and ultrafiltered solute produced
during hemofiltration. If the size of the dissolved
solute is less than the diameter of the hemodiafilter
pores (15,000 daltons) the solute is removed by
convection. Consequently, hemofiltration is more
effective than IHD in removing higher-molecular-
weight substances. A pressure gradient pushes
blood through the hemodiafilter to remove plasma
water (ultrafiltrate). The ultrafiltrate must be
replaced with a solution that contains adequate
amounts of fluid and electrolytes.29
CVVHDF combines diffusion and convection
using a highly efficient hemodiafilter to remove both
solute and fluid.8 Both dialysate and replacement
fluids are required with this modality. The convec-
tive process of solute and fluid removal accom-
plished with both CVVHDF and CVVH is referred to
as ultrafiltration. Convective solute removal during
CVVHDF and CVVH is influenced by solute size and
membrane permeability. This aspect of solute
removal is defined as the sieving coefficient, which is
the degree to which a particular solute passes
through the hemofilter membrane.8 Sieving coeffi-
cients can range from 0 to 1.8 A solute with a sieving
coefficient of 1 will fully penetrate the membrane,
whereas a solute with a sieving coefficient of 0 will
be rejected from the membrane.8 Unfortunately, the
hemodiafilter cannot discriminate between uremic
toxins and nutrients; therefore, the loss of nutrients
with both CVVHDF and CVVH can be significant.8
Not only do CVVHDF and CVVH offer optimal
removal of uremic toxins and fluid, they provide
clearance of middle-molecular-weight molecules
such as mediators of the inflammatory response,
which is why CRRT may have a role in the thera-
peutic management of sepsis.3,7,29
SCUF is a version of CVVH that uses convection
to provide management of fluid overload in patients
with or without ARF.29,31 SCUF primarily addresses
fluid removal and offers minimal solute removal. For
this reason, neither dialysate nor replacement fluids
are components of this modality.29,31 In facilities
where CRRT is not readily used, sustained low-
efficiency dialysis has emerged as a hybrid tech-
nique where IHD is run for 6–12 hours per day to
achieve solute and fluid removal.7,29 This approach
uses standard IHD principles and equipment per-
formed over an extended period in patients who are
not hemodynamically stable enough to tolerate the
physiologic demands of a traditional 3- to 4-hour
run.
In general, solute clearance is weakest in tech-
niques that use convection alone (CVVH, SCUF).32
Diffusive techniques, such as CVVHD, offer
enhanced solute clearance. The combination of con-
vection and diffusion, as with CVVHDF, provides
the greatest clearance of both fluid and solutes.32 In
the absence of conclusive head-to-head trials com-
paring one CRRT modality to another, the selection
of specific CRRT modalities is often based on the
availability of resources and physician prefer-
ence.6,7,29
Four technical aspects of CRRT that that deserve
special consideration because of their relevance to
nutrition are dialysate solutions, anticoagulation,
replacement fluids, and hypothermia.
Dialysate Solutions Used During CRRT
Several different dialysate solutions are commer-
cially available for use with CRRT (Table 3). Many
institutions design customized dialysate solutions
Table 2
Advantages and disadvantages of various continuous renal replacement therapy (CRRT) modalities
CRRT modality Advantages Disadvantages
Continuous venovenous hemodialysis
-Diffusion
Efficient removal of small molecular weight
solutes (urea)
Moderate efficiency
Dextrose-containing dialysate can
Replacement fluids are unnecessary be a significant caloric source
Continuous venovenous hemofiltration
-Convection
Moderate efficiency in removal of middle-
molecular-weight solutes
Significant (10%–17%) protein
losses in ultrafiltrate
Excellent fluid removal Replacement fluids are necessary
Continuous venovenous
hemodiafiltration
Greatest efficiency in removal of middle
molecular weight solutes and fluid
Significant (10%–17%) protein
losses in ultrafiltrate
-Convection and diffusion Adjuvant therapy in the management of
severe sepsis
Replacement fluids are necessary
Dialysate can be a significant
caloric source
Slow continuous ultrafiltraton
-Convection
Safe and effective management of fluid
overload
Low efficiency of solute removal
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that are tailored to various CRRT modalities, equip-
ment, and anticoagulation systems. Dextrose-con-
taining dialysate solutions have been used with
CVVHD and CVVHDF, containing a final dextrose
concentration ranging from 1.5% to 2.5%, which can
represent a significant caloric source.1,8,32,33 The
amount of glucose transferred across the dialysis
membrane can range from 35% to 45% or higher,
depending on the final dextrose concentration and
several interacting variables such as the dialysate
flow rate, the blood filtration rate, the ultrafiltration
rate, and the patient’s blood glucose concentra-
tion.8,32,33 For example, 1 L per hour of dialysate
containing a final concentration of 1.5% dextrose at
43% uptake yields the net absorption of approxi-
mately 526 kcal/d.1,32 Likewise, 1 L per hour of
dialysate containing a final concentration of 2.5%
dextrose at 45% uptake yields the net absorption of
approximately 918 kcal/d.1,32 To promote glycemic
control and avoid overfeeding, nutrition-support
regimens must be modified accordingly to account
for obligatory caloric delivery when dextrose-con-
taining dialysate solutions are used.8,32,33 A better
strategy is to use low-dextrose dialysate solutions
containing a physiologic concentration of dextrose
(0.1% to 0.15%).8,32,33 These dialysate solutions do
not provide significant dextrose calories; in fact,
they can result in a 4% net loss of glucose from the
patient.34
Anticoagulation
Multiple strategies are devised to prevent clotting
within the extracorporeal circuit and maintain the
patency of the hemodiafilter to avoid frequent inter-
ruptions of CRRT. Several forms of anticoagulation
are used during CRRT to extend the life of the
hemodiafilter. These include unfractionated hepa-
rin, 4% and 2% trisodium citrate, and anticoagulant
citrate dextrose-formula A (ACD-A). Heparin is the
most commonly used anticoagulant but has the
disadvantages of causing systemic anticoagulation,
which increases the risk of bleeding and is contra-
indicated in patients with heparin-induced throm-
bocytopenia.35–38 Heparin may also be contraindi-
cated in patients with liver failure and
coagulopathies who are at high risk for bleeding. To
avoid these effects, trisodium citrate has become
more commonly used as an alternative anticoagu-
lant to heparin. Trisodium citrate is used for
regional anticoagulation within the extracorporeal
circuit and has also proven to extend the life of the
filter longer than heparin.37,39 Trisodium citrate,
infused prefilter, exerts its anticoagulant effect
through chelation of ionized calcium, which is a
cofactor in the coagulation cascade.40 Because the
formed citrate-calcium complex is mostly eliminated
in the ultrafiltrate, hypocalcemia is the major com-
plication of trisodium citrate. As such, calcium chlo-
ride is continuously infused during the process, and
the infusion is adjusted according to the serumTa
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ionized calcium levels. The citrate portion that is not
cleared in the ultrafiltrate is subsequently metabo-
lized to bicarbonate in the liver. As such, the
patient’s acid-base status is closely monitored to
avoid alkalemia. Because citrate conversion mainly
occurs in the liver, patients with liver failure may
accumulate citrate, possibly causing anion-gap met-
abolic acidosis and an increased total calcium/ion-
ized calcium ratio of 2.5.41–43 The possibility and
severity of citrate toxicity in patients with liver
failure remains, however, to be determined.43
Another anticoagulant used for regional anticoagu-
lation is ACD-A. ACD-A has also been shown to
extend the life of the hemodiafilter and is associated
with lesser metabolic complications than trisodium
citrate.40,44
When evaluating the nutritional requirements of
a CRRT patient, it is important to consider the
composition of the anticoagulant and the potential
implications of these solutions. In an effort to assist
the reader to investigate some of these issues, a
checklist to evaluate CRRT practices is included
(Table 4).
Replacement Fluids Used During CRRT
CRRT modalities that need fluid replacement
include CVVH and CVVHDF because of their depen-
dency on convection for clearance. Replacement flu-
ids given prefilter minimize procoagulation and
hemoconcentration.29 The selection of replacement
fluids should be individualized to meet the metabolic
demands of the patient. Factors that should be
taken into consideration include the type of dialy-
sate and anticoagulation being used for CRRT, the
electrolyte status, and acid-base balance of the
patient. Depending on the concentration of sodium,
potassium, and magnesium in the dialysate solution
(Table 3) and the serum electrolyte levels of the
patient, management of these electrolytes may be
achieved by adding adequate amounts to the
replacement fluid. Examples of commonly used
replacement fluids include normal saline, 0.45 nor-
mal saline, sodium bicarbonate, or dialysate solu-
tions.
Hypothermia
Hypothermia is a side effect of CRRT that occurs
with an incidence of 2%–50% of patients and is
defined as a core temperature 35°C.45,46 The pri-
mary mechanism by which CRRT causes hypother-
mia is heat loss. Heat is lost to the atmosphere,
through blood tubing, the surface of the hemofilter,
the effluent flow, and through the interaction of the
patient’s blood with room-temperature dialysate
and replacement fluids.46
Hypothermia can mask one of the first signs of
infection by inhibiting the patient’s ability to
mount a fever. Other side effects of hypothermia
include the compromise of host immune defenses;
increases in systemic vascular resistance and
mean arterial pressure; and decreases in heart
rate, cardiac output, and systemic oxygen deliv-
ery.46 Hypothermia has been linked with higher
infection rates in critically ill patients.45,47,48
Conversely, prevention of hypothermia in surgi-
cal patients has been found to decrease postoper-
ative wound infections.29 Warming blankets are
often used to rewarm patients with hypothermia.
However, the ideal practice would be to prevent
hypothermia, rather than treat it, by using a
fluid warmer as a companion to the CRRT
machine.
Specialized Nutrition Support in Patients
Treated With CRRT
Primary nutritional goals in the management of
ARF are maintenance or improvement of nutritional
status without exacerbating metabolic derange-
ments, enhancement of wound healing, optimal
resistance to infection, and reduced mortality.1 The
nutritional implications of CRRT are significant and
vary with the type and intensity of each modality.10
Nutrition Assessment
The assessment and diagnosis of malnutrition
is difficult in patients with ARF.5 Body weight,
body mass index, anthropometric measurements,
and serum protein levels are of little value in the
nutrition assessment of these critically ill, fluid-
overloaded patients.1 Subjective global assess-
ment (SGA) is a simple tool with high sensitivity and
specificity that is composed of a carefully organized
outline of a patient’s dietary and past medical his-
tory, physical examination, and functional assess-
ment.49,50 Using SGA in a prospective noninterven-
tional study, Fiaccardori et al5 found that 42% of
patients with ARF requiring CRRT had severe mal-
nutrition and that preexisting malnutrition was a
statistically significant and independent predictor of
a negative hospital outcome. Even though tradi-
tional nutrition assessment tools may be unreliable
for this population and SGA is not widely used by
ICU clinicians, it must be recognized that malnutri-
tion is highly prevalent in patients with ARF.
Table 4
Checklist to evaluate continuous renal replacement therapy
(CRRT) practices used at your institution
✓ Does the patient have indications for the initiation of
CRRT?
✓ What CRRT modality is used?
✓ What is the composition of the dialysate, depending on
the CRRT modality?
✓ What form of anticoagulation is used?
✓ What form of anticoagulation should be used in patients
with liver failure undergoing CRRT?
✓ What is the composition of the replacement fluids
according to the CRRT modality?
✓ How is hypothermia being addressed in patients
undergoing CRRT?
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Protein Requirements During CRRT
The delivery of adequate protein to patients with
ARF is an important component of the nutritional
regimen because of their hypercatabolism,6 obliga-
tory use of protein as a preferred fuel source during
the stress response,2 and the likelihood of significant
protein losses in CRRT effluent.1,2 The high-flux
membrane used within the hemodiafilter is perme-
able to plasma proteins. Protein losses are higher
during convection-based (CVVH and CVVHDF)
than diffusion-based (CVVHD) CRRT because of the
type of membrane used with each modality.2,51,52 In
general, centrally infused protein losses into CRRT
effluent range from 10% to 17% and should be taken
into consideration when determining protein
requirements.27,34,53,54
Consensus in the literature for protein delivery in
patients undergoing CRRT is 1.5–2 g protein/
kg.1,7,32,33,53 However, up to 2.5 g/kg of protein has
been advocated to promote positive nitrogen bal-
ance.27,34,53,54 Disadvantages of high-protein deliv-
ery may include the exacerbation of uremia,
increased demand on hepatic and renal function,
and increased costs.7,10,53
Energy Requirements During CRRT
Energy expenditure is not greatly affected by
ARF, in and of itself. The underlying pathology
leading to the patient’s critical illness plays the
biggest role in determining energy expendi-
ture.1,2,6,10,27,32 The use of indirect calorimetry
allows nutrition support to be tailored to the indi-
vidual patient’s needs and is the gold standard for
determining energy expenditure in critically ill
patients.1,32,54,55 It is recommended to feed at no
higher than 130% of the patient’s resting energy
expenditure.1,10,52,55 Indirect calorimetry also facil-
itates the recognition of hypometabolism associated
with CRRT. Hypothermia has been shown to influ-
ence energy expenditure by inducing a hypometa-
bolic response in the patient.32 The decrease in core
temperature is associated with a 20% reduction in
oxygen consumption, corresponding to a 7.1%
decrease in energy expenditure.32,56 A potential lim-
iting factor related to indirect calorimetry is that
CRRT may result in extracorporeal removal of CO2,
but whether or not these losses are significant
enough to affect the validity of indirect calorimetry
is unclear.54,55,57–59 In the absence of IC, many
equations exist for predicting the caloric require-
ments of critically ill patients. Clinical consensus is
to provide CRRT patients with 25–35 kcal/kg.7,10,27
The avoidance of overfeeding is crucial in these
patients.10 Nutrition-support regimens must be
modulated around obligatory calories from CRRT
dialysate, anticoagulation, replacement fluids, and
other dextrose- or lipid-containing IV medications,
when indicated. Low-dextrose dialysate solutions
are available and should be used whenever possible
to avoid overfeeding, promote glucose control, and
minimize the need to modulate nutrition regimens.
Enteral Nutrition During CRRT
The initiation of nutrition support should begin
as soon as feasible after resuscitation and hemody-
namic stabilization. As with most ICU populations,
the enteral route is the preferred route for nutrition
support in patients with ARF because it can pre-
serve gut function, possibly enhance immunity, and
decrease episodes of bacteremia and infec-
tion.2,6,10,27 Small bowel enteral access is beneficial
because this population is likely to develop gastro-
paresis and may not always tolerate elevation of the
head of bed 30 degrees. Low infusion rates using a
standard polymeric formula are appropriate until
tolerance is assured.10,32,60 When diluted standard
enteral formulas are used to account for obligatory
calories from dextrose-containing dialysate, modu-
lar protein is often needed to meet protein goals
without overfeeding from a caloric standpoint.32,33
Enteral formulas designed for renal failure are
unwarranted because fluid, protein, and electrolyte
restrictions become unnecessary during CRRT.60
The use of “wound-healing” enteral formulas is con-
troversial because of their high vitamin A and vita-
min C content. Additional water-soluble vitamins
should be administered to replace CRRT losses by
using a renal multivitamin delivered via the
patient’s nasogastric tube.1,2,6
It has been theorized that patients undergoing
CRRT may benefit from immune-enhancing enteral
formulas.6,27 Most patients requiring CRRT are
metabolically stressed, with altered immune func-
tion. Immunostimulatory nutrients like arginine
and nucleotides may exacerbate the proinflamma-
tory response counterproductively, especially in
patients with sepsis.61,62 Caution is warranted with
the use of immune-enhancing nutrients in patients
having undergone solid organ transplants because
of their immunostimulatory functions, which could
increase risk of organ rejection. In view of the lack of
randomized controlled studies evaluating the effects
of immune-enhancing nutrients in patients with
ARF receiving CRRT, recommendations on this sub-
ject cannot be provided at this time.10
Monitoring tolerance to enteral nutrition is vital
to the avoidance of nutrition-related complications.
Clinical abdominal examinations should be followed
for signs of ileus, abdomen distention, or pain. Cau-
tion should be used in patients receiving enteral
feedings during acute hypotension or hemodynamic
instability requiring vasopressor support.63,64 Dual
support with parenteral nutrition (PN) and tube feed-
ing in order to achieve the benefits of enteral nutrition
while meeting target calories and protein with PN is
an acceptable approach, when indicated.2,6,10,54
Indeed, the majority of the prospective, randomized,
controlled trials evaluating nutrition during CRRT
used PN as the route of nutrition support. Very few
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systematic studies on enteral nutrition and the
impact of ARF on gastrointestinal function have
been published. However, in a prospective, multi-
center cohort study, Metnitz et al4 reported that
enteral nutrition was associated with improved sur-
vival in patients undergoing CVVH and CVVHDF. A
subsequent study corroborated their findings by
further demonstrating that the presence of enteral
feeding, even after adjusting for predicted risk of
death, had a statistically significant benefit on out-
come in CRRT patients.54
PN During CRRT
PN is appropriate when the gastrointestinal tract
cannot be used for enteral feeding. A balanced PN
regimen usually provides 10%–20% of total daily
calories from amino acids, 50%–60% of calories from
dextrose, and 20%–30% of calories from lipid emul-
sions. Designer amino acid formulations are expen-
sive and offer no clinical benefit to patients receiving
CRRT.27 Limiting dextrose infusion rates to 4–5
mg/kg/min in adult patients is indicated in critically
ill adult patients.65,66 The modulation of amino acids
and dextrose around obligatory loss and net absorp-
tion from CRRT is an important aspect of designing
PN regimens. However, it should be noted that there
are negligible lipid losses across the hemodiafilter.
Lipid clearance may be reduced in critically ill
ARF patients because of decreased activity of the
lipoprotein lipase enzyme.10 Lipid administration
should be limited to 1 g/kg/day, with the routine
measurement of serum triglyceride levels to avoid
hypertriglyceridemia.2,3,10 The 20%–30% lipid emul-
sions have a lower potential for hypertriglyceride-
mia than the 10% emulsion because of their lower
phospholipid content.67,68 Withholding lipid infu-
sion is recommended when serum triglyceride levels
are 400 mg/dL in adult patients. Providing 300 mL
of 20% lipid biweekly prevents essential fatty acid
deficiency. In theory, the use of parenteral medium-
chain triglycerides (MCT) may result in lower serum
triglyceride levels than long-chain triglycerides
(LCT) because of their faster oxidation. However,
the benefits of using mixed MCT/LCT lipid formula-
tion in ARF patients are yet to be determined.69 At
this time, MCT/LCT lipid formulations are not com-
mercially available in the US.
Typically, restriction of potassium, magnesium,
and phosphorus in PN is unnecessary for CRRT
patients. Serum electrolyte levels are largely dic-
tated by the electrolyte composition of the dialysate
solutions and the efficiency of CRRT in solute clear-
ance. Losses of potassium, calcium, phosphorus, and
magnesium in CRRT effluent and urine should be
anticipated and treated aggressively. The develop-
ment of profound hypophosphatemia during unin-
terrupted CRRT, especially with use of CVVHDF,
because of hyperexcretion and intracellular shifting
is predictable and should be treated accordingly.32
The chloride:acetate ratio can be adjusted in PN
according to acid-base status. Maximizing acetate, a
bicarbonate precursor, in PN helps correct the met-
abolic acidosis, but this should be weighed against
other acetate, citrate, or bicarbonate sources related
to CRRT.
Supplementation of vitamins and trace elements
in ARF is largely derived from data in patients with
CRF. Vitamins70 and trace elements71 are usually
added to PN according to the recommendations of
Nutritional Advisory Group to the American Medi-
cal Association. Commercially available parenteral
vitamin products contain a mix of water- and fat-
soluble vitamins and are generally adequate for
most ARF patients.
Trace Elements in ARF Patients
Trace-element requirements for ARF patients
treated with CRRT represent an important area of
research. Most recommendations regarding mineral
requirements during ARF are extrapolated from
research conducted in CRF patients. Of the avail-
able studies, many of the findings on trace-element
homeostasis in ARF represent unspecific alterations
within the spectrum of acute-phase response, and
these alterations may not necessarily reflect specific
effects induced by ARF.
Alterations in blood and tissue trace element
levels have been described in CRF patients under-
going IHD.72–78 Increased72,74 or decreased plasma
zinc levels,75,76,78 increased plasma copper lev-
els,72,74,76,78 and decreased plasma and erythrocyte
selenium levels72,77 have been reported. A possible
zinc deficiency–induced gonadal dysfunction in IHD
patients has been proposed, which was reversed by
adequate zinc supplementation.79 Zinc supplemen-
tation caused reversal of hypogeusia observed in
CRF patients.80 Zinc supplementation may also
improve lymphocyte function because of zinc defi-
ciency in uremic patients by possibly correcting this
abnormality.81 However, the potential for these
alterations, their clinical implications, and the
response to zinc supplementation are largely
unknown in patients with ARF.
Reduced serum selenium levels in CRF patients
were associated with a lower platelet glutathione
peroxidase activity and possible increase in cardio-
vascular complications compared with the patients
without cardiovascular complications.82 Because
data on trace element abnormalities are mostly
derived from CRF patients, it is difficult to extrap-
olate these data to ARF patients who may have
other concurrent diseases and are on a shorter
duration of dialysis.83 Also, historically, there have
been difficulties in assessing trace element status in
ARF patients. This is because of several factors,
including trace-element tissue redistribution during
stress, changes in trace element plasma protein
binding, methodological assay difficulties, and ques-
tionable correlation between blood trace-element
levels and tissue stores.
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Trace Elements in CRRT Patients
Trace elements have small molecular weights to
pass through the hemodiafilter membranes, and
alteration in plasma protein binding during critical
illness could affect trace-element homeostasis dur-
ing CRRT therapy. In vitro data showed that trace
elements, including selenium, chromium, copper,
and zinc, are cleared during CVVH. Manganese
removal by CVVH appears to be least affected,
whereas significant selenium clearance occurs.84
Few studies evaluated the behavior of trace ele-
ments in CRRT patients.85–88 Van Renterghem et
al85 evaluated the effects of CVVHDF on the serum
levels of 12 minerals in 5 patients. Lower serum
selenium and zinc levels and higher serum copper
levels compared with reference values were
reported. Dialysate concentrations of copper and
zinc were lower than the corresponding serum val-
ues, and selenium levels were below the detection
level of the analytical methods. The replacement
fluid contained very low concentrations of copper,
selenium, and zinc, below those for respective serum
levels. The investigators concluded that the low
serum selenium and zinc levels were caused by their
low concentrations in the replacement fluid. It was
also suggested that the high serum copper levels
were not related to CVVHDF because of low and
constant dialysate and replacement fluid values but
were rather related to copper and zinc competition
to plasma protein binding. Limitations to this study
include a small sample size, the absence of baseline
serum mineral levels before initiation of CVVHDF,
and failure to measure trace mineral levels in the
spent dialysate.
In a larger study by Story et al,86 blood trace
element levels were measured in 9 normal subjects,
9 ICU patients, and 8 ICU patients treated with
CVVH. In the CVVH group, blood samples were
collected before CVVH initiation and at 30 minutes
and 24 hours after CVVH initiation. Ultrafiltrate
samples were collected at 30 minutes and 24 hours
after CVVH initiation. Study results showed a sta-
tistically significant reduction in blood selenium and
zinc levels in the CVVH group compared with con-
trols. Chromium and copper losses occurred in the
ultrafiltrate. However, chromium blood levels were
increased. Ultrafiltrate losses of manganese, sele-
nium, and zinc were small or undetectable, and the
investigators concluded that the significance of
ultrafiltrate loss of these trace elements was
unclear. There was no report on whether selenium,
manganese, and zinc were present or not in the
ultrafiltrate, and it was unknown whether patients
were receiving nutrition as a potential source of
trace elements.
In a study of trauma patients treated with CRRT,
zinc losses occurred with CVVH and CVVHD.87
Study results showed a small amount of zinc in the
effluent with both CVVH and CVVHD. Trisodium
citrate was used as an anticoagulant, which was
contaminated with 6.2  0.4 mol/L of zinc. This
contamination could have influenced the study
results. Because minimal amounts of zinc were
detected in the ultrafiltrate, the investigators con-
cluded that zinc losses did not amount to providing
additional zinc to patients treated with CRRT who
are receiving standard zinc amounts in their PN.
In a prospective, randomized, crossover study,
Berger et al88 evaluated the effects of CVVHDF on
the elimination of copper, selenium, and zinc in 11
critically ill adult patients with ARF. Each patient
received 2 different replacement fluids, including
bicarbonate and lactate solution. Patients were
receiving PN with micronutrient supplements.
Plasma trace element levels were collected at base-
line and at the end of the CRRT session. The effluent
solution was also analyzed for trace element levels.
Study results showed that all 3 elements were
eliminated in the effluent. Most significant was the
elimination of selenium at 2 times the daily supple-
mented intake. Because selenium is a cofactor for
the antioxidant glutathione peroxidase enzymes, it
is of concern that selenium deficiency may result in
decreased antioxidant defense activities. About 30%
of the supplemented copper in PN was lost.
Although zinc was lost in the effluent, a positive zinc
balance was reported. The investigators related the
positive zinc balance to zinc contaminants in
replacement fluids, which provided zinc in addition
to what was normally added to PN. Only very small
quantities of selenium and no measurable amounts
of copper were detected in the replacement fluids.
In summary, plasma levels of trace elements
seem to be altered during CRRT. The ultrafiltration
rate appears to be a significant factor affecting trace
element clearance during CVVH.84 According to the
few available studies, the extent of trace element
clearance has been variable. This variation may be
affected by the type of CRRT used, patient popula-
tion, duration of CRRT, and the sensitivity of assay
methods used for measuring trace elements. Fur-
ther studies are needed to assess the clinical impact
of changes in trace-element levels and to determine
the actual requirements of trace-element supple-
mentation during CRRT.
Vitamins in CRRT Patients
CRRT primarily affects water-soluble vitamins, but
fat-soluble vitamins are unlikely to be affected.10,27
Loss of water-soluble vitamins during dialysis has
been reported. Berger et al88 reported significant
losses of thiamin in the effluent during CVVHDF
therapy in critically ill ARF patients. The elimina-
tion of thiamin exceeded 1.5 times the standard
daily provision of thiamin in the parenteral multi-
vitamin mix. Vitamin C losses may also occur during
CRRT at a level that is equivalent to the RDI.27 In
the study by Story et al,86 vitamin C was detected in
the ultrafiltrate during CVVH therapy. Decreased
blood levels of vitamin C and vitamin E were also
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reported.86 However, the clinical significance of
these changes is unknown. Vitamin C administra-
tion should be given cautiously because of risk of
oxalate crystallization.27 The current recommenda-
tion is to limit vitamin C intake to 200 mg/day.10
Commercial parenteral multivitamin formulations
have been reformulated to contain 200 mg vitamin
C. Vitamin C has many physiologic functions,
including its role as an antioxidant. Whether addi-
tional vitamin C is required during CRRT remains
to be determined. Additionally, there may be deple-
tion of other endogenous antioxidants in ARF.27
However, the role of antioxidant supplementation in
ARF patients undergoing CRRT is unknown.10,89
There is a theoretical concern about vitamin A
accumulation and potential toxicity in renal-failure
patients. Elevated serum vitamin A and retinol-
binding protein levels occur in patients receiving
dialysis because of reduced renal metabolism of
these substances in renal failure. This mainly may
become a problem in CRF patients. However, vita-
min A toxicity, which is a factor of the free unbound
serum vitamin A, is unlikely to occur during the
relatively short time period of CRRT therapy.
In summary, more research is needed to deter-
mine the actual vitamin requirements in CRRT
patients. Although losses of thiamin and vitamin C
have been reported, the clinical impact of these
losses remains unknown. Also, the behavior of other
water- and fat-soluble vitamins is undetermined in
this population.
Monitoring Parameters During Nutrition
Support in Patients With ARF
Tight Glycemic Control
Hyperglycemia is common in critically ill patients
with ARF as a consequence of insulin resistance and
hepatic gluconeogenesis.6,10 Poor glucose control
may result in significant complications and
increased infectious risk. In a landmark study by
van den Berghe et al,90 tight glycemic control was
shown to decrease mortality in critically ill patients.
The investigators also concluded that intensive
insulin therapy prevented ARF.90 However, the goal
of maintaining glucose levels between 80 and 110
mg/dL is particularly challenging for ARF patients
requiring CRRT. Patients receiving high dextrose
loads from CRRT dialysate will absorb more dex-
trose when blood glucose levels are lower than the
dialysate glucose concentration.34 Conversely, when
low dextrose dialysate solutions are used, glucose
losses into the effluent will be directly proportional
to blood glucose levels; therefore, losses can be
decreased by tight glycemic control.34 Significant
amounts of insulin may be required by this popula-
tion. The addition of regular insulin to PN may lead
to hypoglycemia should CRRT become unexpectedly
interrupted, especially if the dialysate or replace-
ment fluids contain dextrose. Therefore, the safest
approach to glucose control in CRRT patients is
through a continuous regular insulin infusion,
which allows hourly titration of insulin delivery
according to the patient’s clinical and metabolic
status.
Acute Protein Status
Plasma protein levels may not be very useful as
nutritional markers during the early phases of crit-
ical illness and ARF for several reasons. Hydration
status will affect plasma proteins, which can mani-
fest as either hemodilution or hemoconcentration of
values.2 The acute-phase response to metabolic
stress that is so common in ARF patients is associ-
ated with the reprioritization of plasma protein
synthesis within the liver, resulting in lower serum
prealbumin and albumin levels, regardless of nutri-
tional status. To corroborate whether various
plasma proteins are low because of malnutrition vs
the acute- phase response to inflammation, the mea-
surement of C-reactive protein can be obtained as
this plasma protein is a positive acute-phase reac-
tant.91 Following trends in plasma protein levels can
be meaningful in this regard. However, because
prealbumin is degraded in the healthy kidney, levels
may be slightly higher in patients with ARF. As
such, aiming for a prealbumin level 30 mg/dL
would be the goal in achieving optimal plasma
protein status for this population.92
Nitrogen-Balance Studies
Nitrogen-balance studies are widely used as the
gold standard for assessing protein status and
degree of catabolism vs anabolism among research-
ers, and yet the utility and accuracy of nitrogen-
balance studies outside the research setting, for this
population, is controversial. The reliability of uri-
nary urea nitrogen (UUN) levels to accurately cal-
culate nitrogen balance is compromised with creat-
inine clearance of 50 mL/min.32 Interruptions in
CRRT decrease the accuracy of 24-hour UUN mea-
surements. UUN losses in effluent, dialysate, and
any urine production must be accounted for in order
for studies to be accurate.32 An important question
to ask is whether monitoring nitrogen balance would
change what is given to the patient in terms of
protein provision. Increasing protein delivery may
reduce, but will not eliminate, cumulative nitrogen
deficits.32
Patient Case
A 35-year-old white man presented to the emer-
gency department with progressive shortness of
breath after a recent “viral” illness. His past medical
and surgical history were noncontributory. The
patient was diagnosed with severe bacterial endo-
carditis affecting his aortic valve.
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Nutrition Parameters
Nutrition parameters were as follows:
Height: 5 feet 11 inches
Actual body weight: 99 kg
Usual body weight: 89 kg
Ideal body weight: 78.2 kg
Predicted energy requirements: 2225–3115 kcal/
day (25–35 kcal/kg)
Protein requirements for CRRT: 133–178 g/day
(1.5–2 g/kg)
Hospital Course
The patient was emergently taken to the operat-
ing room for an aortic valve replacement. Postoper-
atively, he became hypotensive and hemodynami-
cally unstable, requiring multiple vasopressors to
support his blood pressure. His urine output fell to
400 mL per day, and did not respond to IV fluids,
plasma expanders, or diuretic therapy. It became
evident that the patient had developed prerenal
ARF secondary to perioperative ischemia and renal
hypoperfusion. On hospital day 2, CVVHDF was
initiated using a 2.5% dextrose-containing dialysate
(918 kcal/day net absorption), trisodium citrate for
regional anticoagulation, and normal saline as
replacement fluids. The patient developed hypergly-
cemia with the induction of CRRT, despite having no
history of diabetes mellitus, and required an insulin
drip to achieve tight glycemic control. By hospital
day 8, the patient had become hemodynamically
stable, and he began to make urine. As the patient
became more alert and oriented, he self-extubated
from mechanical ventilation, and he was success-
fully converted over to IHD for ongoing dialytic
support 3 times per week. See Table 5 for laboratory
and nutrition-related trends.
Nutrition Course
On hospital day 2, a nasoenteric feeding tube was
placed into his small bowel to begin enteral nutri-
tion support using a standard, isotonic formula.
Enteral nutrition was not well tolerated by the
patient secondary to hemodynamic instability,
abdominal distention, and high nasogastric output.
Therefore, on hospital day 4, the tube feeding was
decreased to 20 mL/h for gut stimulation, and PN
was started with a solution containing 75 g protein,
50 g dextrose, and 10 g fat, which was modulated
around obligatory calories from dextrose-containing
dialysate and lipid-containing sedation (propofol).
The PN electrolytes were geared toward his labora-
tory values (Table 5). Insulin was not added to the
PN solution to protect the patient from hypoglyce-
mia if the CRRT system was interrupted for any
unforeseen reason. A renal multivitamin prepara-
tion was delivered via nasogastric tube to replace
water-soluble vitamin losses via spent CRRT ultra-
filtrate. On hospital day 5, PN was advanced to
“goal” of 150 g protein (1.7 g/kg) and 2388 kcal/day,
including dextrose calories absorbed from CRRT
dialysate, according to indirect calorimetry, which
revealed a resting energy expenditure of 2350 kcal/
day. On hospital day 8, total PN was reformulated
after the patient was converted to IHD to provide
125 g protein (1.4 g/kg) and 2345 kcal/day. Unfortu-
nately, the patient inadvertently pulled out his
central IV line for PN and nasogastric tube on
hospital day 9 during a moment of agitation. After a
successful bedside swallowing study on hospital day
10, the patient began receiving a renal diet, and a
calorie count was ordered to document the adequacy
of his oral intake. Pertinent medications included a
renal multivitamin, phosphorus binder with meals,
and a stool softener.
Conclusions
Nutrition support in critically ill patients with
ARF is complex, and the metabolic alterations
caused by the stress response, and the supportive
therapies designed to treat it, must be taken into
consideration in order to design optimal nutrition
regimens for this population. The trend toward the
use of CRRT as the dialytic modality of choice in the
ICU for patients with ARF makes this area of
nutrition practice of great interest to the clinician.
By obtaining a solid foundation of knowledge about
the nutritional implications of CRRT, the precision
of nutrition support practices will undoubtedly
improve the quality of care and clinical outcomes. A
Table 5
Patient case: nutrition parameters and indices
Hospital day BUN
mg/dL
Cr
mg/dL
K
mEq/L
Phos
mg/dL
Mg
mEq/L
I. Ca
mg/dL
Caloric
delivery
Protein
delivery, g/d
2 37 3.6 6.3 6.5 1.6 3.7 918 0
3 40 4 4.5 5.6 1.4 2.9 2032 19
4 31 3.8 3.6 2 2 6 2602 94
5 33 3.9 4.1 3.7 1.9 5.1 2388 150
8 74 5.6 4.3 4.5 2.1 4.8 2345 125
10 89 9.5 3.9 8.3 2.2 3.6 2180 95
BUN, blood urea nitrogen; Cr, creatinine; K, potassium; Phos, phosphorus; Mg, magnesium; I. Ca, ionized calcium.
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summary of our recommendations for nutrition sup-
port during CRRT can be found in Table 6.
Clinical research related to the nutrition implica-
tions of CRRT is still lacking, and many questions
remain unanswered. The efficacy of enteral vs PN
during CRRT needs further study. The use of indi-
rect calorimetry and, hence, avoidance of under- or
overfeeding on outcome is unknown in this popula-
tion. The vitamin and trace element needs of ARF
patients requiring CRRT are poorly understood. The
role of immunonutrition and antioxidant therapy
requires further elucidation.
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